Taro Pharmaceutical Industries Long Term Debt

Taro Pharmaceutical Industries (TARO) currently reports a long-term debt of $0 as of March 2024. That compares with $-3.3M in the prior-year period — up 100.0% year over year. Use the charts on this page to explore Taro Pharmaceutical Industries's long-term debt history and peer comparisons.

Taro Pharmaceutical Industries's long-term debt increased from $-3.3M to $0 — a 100.0% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taro Pharmaceutical Industries reported $0 in long-term debt as of March 2024. That compares with $-3.3M in the prior-year period — up 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Taro Pharmaceutical Industries, and consider following TARO for alerts when major investors trade the stock.

Taro Pharmaceutical Industries is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TARO with unrelated industries.